Magnolia Medical has developed the Steripath Initial Specimen Diversion Device, a pre-assembled and sterile blood-collection system that diverts the initial contaminated blood to reduce false-positive results in blood cultures. This technology addresses the issue of blood culture contamination, leading to improved diagnostic accuracy for sepsis testing and significant reductions in unnecessary antibiotic use and hospital costs.
Funding
$46M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
RISAFounders
Product
Problem
Blood culture contamination leads to false-positive sepsis diagnoses, resulting in unnecessary antibiotic use, increased patient harm, and significant healthcare costs. Current blood collection methods often fail to eliminate contaminants present on the skin or catheter hub, leading to inaccurate test results. This diagnostic uncertainty complicates antimicrobial stewardship efforts and impacts key hospital quality outcome metrics.
Solution
Magnolia Medical Technologies offers the Steripath Initial Specimen Diversion Device, a sterile, all-in-one system designed to reduce blood culture contamination and improve sepsis testing accuracy. Steripath diverts the initial portion of blood, which is most likely to contain contaminants, away from the collection vials. This process reduces false-positive blood culture results, leading to more appropriate antibiotic use and improved patient outcomes. Clinical studies have demonstrated significant reductions in contamination rates when using Steripath for blood cultures collected via peripheral venipuncture and peripheral IV starts.
Target Audience
The primary target audience includes hospitals, healthcare systems, clinical laboratories, infection prevention specialists, and healthcare professionals focused on improving sepsis diagnosis and antimicrobial stewardship.
Features
- Pre-assembled and sterile blood collection system for initial specimen diversion
- FDA 510(k)-cleared for reducing blood culture contamination
- Integrated design for ease of use and consistent performance
- Available in standard and micro configurations to accommodate different patient populations
- Compatible with standard blood culture collection techniques
- Supports diagnostic stewardship and antimicrobial stewardship programs
- Peer-reviewed clinical studies demonstrating significant contamination rate reductions